




Name	Loredana Ruggeri	
Current Position	MD, PhD, Director of BMT Immunology Laboratory	
Country	Italy	
Major Field	Hematology and Clinical Immunology	

Educational Background

2003, PhD in Biotechnologies of Bone Marrow Transplantation, University of Perugia

1998, Board-certif. Hematology, Medical School, University of Perugia

1994, MD Degree, Medical School, University of Perugia

Professional Experience

2017-present: Clinical Researcher

2011-2017, Assistant Professor, Division of Hematology and Clinical Immunology, University of Perugia, Italy

2010-2015, Scholar, Division of Hematology and Clinical Immunology, University of Perugia, Italy

2006-2009, Fellow, Division of Hematology and Clinical Immunology, University of Perugia, Italy

1998-1999, Fellow, Division of Hematology and Clinical Immunology, University of Perugia, Italy

Other Experience and Professional Memberships

2013: National Eligibility for Associate Professor

2016: National Eligibility for Full Professor

Other Experience and Professional Memberships

Grants as Principal Investigator

2009: Special Fellowship in Clinical Research from Leukemia and Lymphoma Society.

2010-2015: Special Scholarship in Clinical Research from Leukemia and Lymphoma Society.

2018: Ricerca finalizzata, Ministry of Health

Honors

1998 "Ermanno Paschetto e Francesco Scaferla" Fellowship of Fondazione Italiana per la Ricerca sul Cancro.

2000 Award for Best Oral Presentation, 18th International Natural Killer Cell Workshop and 6th Annual Meeting of the Society for Natural Immunity, Marseille, France.



2002 Van Bekkum Award for 1st best abstract "Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants" and Opening Ceremony Plenary Presentation, Annual E BMT Meeting. Montreaux, Switzerland.

Main Scientific Publications

Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, **Ruggeri L**, Barbabietola G, Aristei C, Latini P, Reisner Y, and Martelli MF: Transplantation for high-risk acute leukemia with high doses of T cell-depleted hematopoietic stem cells from haploidentical "three loci" incompatible donors. N Eng J Med, 339:1186,1998

Ruggeri L, M Capanni, M Casucci, I Volpi, A Tosti, K Perruccio, E Urbani, RS Negrin, MF Martelli, and A Velardi. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 94:333-339, 1999

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002 Mar 15;295(5562):2097-100.

Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007 Jul 1;110(1):433-40

Mancusi A, **Ruggeri L**, Urbani E, Pierini A, Massei MS, Carotti A, Terenzi A, Falzetti F, Tosti A, Topini F, Bozza S, Romani L, Tognellini R, Stern M, Aversa F, Martelli MF, Velardi A. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces non-relapse mortality. Blood. 2015

Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells.

Ruggeri L, Urbani E, André P, Mancusi A, Tosti A, Topini F, Bléry M, Animobono L, Romagné F, Wagtmann N, Velardi A. Haematologica. 2016 May;101(5):626-33

Martelli MF, Di Ianni M, **Ruggeri L**, Pierini A, Falzetti F, Carotti A, Terenzi A, Reisner Y, Aversa F, Falini B, Velardi. "Designed" grafts for HLA-haploidentical stem cell transplantation. Blood. 2014 Feb 13;123(7):967-73.

Martelli MF, Di Ianni M, **Ruggeri L**, Falzetti F, Carotti A, Terenzi A, Pierini A, Massei MS, Amico L, Urbani E,



Del Papa B, Zei T, Iacucci Ostini R, Cecchini D, Tognellini R, Reisner Y, Aversa F, Falini B, Velardi. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. *Blood*. 2014 Jul 24;124(4):638-44.

Ruggeri L, Vago L, Eikema DJ, de Wreede LC, Ciceri F, Diaz MA, Locatelli F, Jindra P, Milone G, Diez-Martin JL, Pérez-Simón JA, Merluzzi M, Koster L, van der Werf S, van Biezen A, Toubert A, Nagler A, Chabannon C, Bonini C, Velardi A. Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. *Bone Marrow Transplant*. 2021 Mar 25.

Pierini A, **Ruggeri L**, Carotti A, Falzetti F, Saldi S, Terenzi A, Zucchetti C, Ingrosso G, Zei T, Iacucci Ostini R, Piccinelli S, Bonato S, Tricarico S, Mancusi A, Ciardelli S, Limongello R, Merluzzi M, Di Ianni M, Tognellini R, Minelli O, Mecucci C, Martelli MP, Falini B, Martelli MF, Aristei C, Velardi A. Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. *Blood Adv*. 2021 Mar 9;5(5):1199-1208.

Ruggeri L, Urbani E, Chiasserini D, Susta F, Orvietani PL, Burchielli E, Ciardelli S, Sola R, Bruscoli S, Cardinale A, Pierini A, Piersma SR, Pasquino S, Locatelli F, Ramarli D, Velardi E, Binaglia L, Jimenez CR, Holländer GA, Velardi A. Donor natural killer cells trigger production of β -2-microglobulin to enhance post-bonemarrow transplant immunity. *Blood*. 2022 Dec 1;140(22):2323-2334.

Ruggeri L, Eikema DJ, Bondanza A, Noviello M, van Biezen A, de Wreede LC, Crucitti L, Vago L, Ciardelli S, Bader P, Koc Y, Locatelli F, Veelken JH, Gruhn B, Evans P, Chabannon C, Toubert A, Velardi A. Mother Donors Improve Outcomes after HLA Haploidentical Transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. *Transplant Cell Ther*. 2022 Apr;28(4):206.e1-206.e6.
